Abstract
TDO2 is more highly expressed than the nonhomologous TRP-catabolizing enzyme IDO1 in TNBC. We find that TDO2 knockdown can lead to a compensatory increase in IDO1. Therefore, we tested a newly developed TDO2/IDO1 dual inhibitor and found that it decreases TRP catabolism, anchorage-independent survival, and invasive capacity.
©2024 The Authors; Published by the American Association for Cancer Research.
MeSH terms
-
Cell Line, Tumor
-
Female
-
Humans
-
Indoleamine-Pyrrole 2,3,-Dioxygenase* / antagonists & inhibitors
-
Indoleamine-Pyrrole 2,3,-Dioxygenase* / metabolism
-
Neoplasm Invasiveness*
-
Triple Negative Breast Neoplasms* / drug therapy
-
Triple Negative Breast Neoplasms* / metabolism
-
Tryptophan Oxygenase / antagonists & inhibitors
-
Tryptophan Oxygenase / genetics
-
Tryptophan Oxygenase / metabolism
-
Tryptophan* / metabolism
Substances
-
Tryptophan
-
Indoleamine-Pyrrole 2,3,-Dioxygenase
-
IDO1 protein, human
-
Tryptophan Oxygenase